Lung Cancer Risk in Type 2 Diabetes With COPD: SGLT2 Inhibitors vs. Sulfonylureas
Samsung Medical Center
Samsung Medical Center
Centre Hospitalier Régional d'Orléans
Weill Medical College of Cornell University
University of Pittsburgh
Corcept Therapeutics
Centre Hospitalier Universitaire de Liege
Corcept Therapeutics
University of Jaén
Universitätsklinikum Hamburg-Eppendorf
Harvard School of Public Health (HSPH)
Kuwait University
Corcept Therapeutics
University of North Carolina, Chapel Hill
Kyungpook National University Chilgok Hospital
Ohio State University Comprehensive Cancer Center
Shanghai 10th People's Hospital
Mansoura University
Post Graduate Institute of Medical Education and Research, Chandigarh
University of Helsinki
Case Comprehensive Cancer Center
Kyungpook National University Chilgok Hospital
Duke University
Boston University
William Paterson University of New Jersey
Corcept Therapeutics
Liverpool John Moores University
Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
University of Eastern Finland
Albert Einstein College of Medicine
University of Guelph
Washington University School of Medicine
University of Michigan
Harokopio University
University of Southern California
University of Southern California
Canadian Network for Observational Drug Effect Studies, CNODES
The University of Texas Health Science Center at San Antonio
Novo Nordisk A/S
GlaxoSmithKline
Gangnam Severance Hospital
Mayo Clinic
Odense University Hospital